The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure with reduced ejection fraction (HFrEF). The investigators will also determine the effects of EVOO on functional capacity and quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
At least 4 tablespoons of extra-virgin olive oil per day
Strelitz Diabetes Center (Williams Hall)
Norfolk, Virginia, United States
Change in 24-hour dietary recall monounsaturated fatty acids (MUFA)
Measured with validated 24-hour dietary recall (non-self administered)
Time frame: At baseline, and 12-week
Change in dietary compliance (plasma monounsaturated fatty acids)
Measured by changes in biomarkers of monounsaturated fatty acids (MUFA) consumption. Plasma concentrations of MUFA reflect the consumption of a diet rich in MUFA fatty acids, such as oleic acid found in extra-virgin olive oil, making them reliable biomarkers of dietary adherence.
Time frame: At baseline and 12-week
6-minute walk test distance
Time frame: Baseline, 12-week
Change in quality of life (Kansas City Cardiomyopathy Questionnaire)
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered instrument used to evaluate the quality of life of patients with heart failure. The score ranges from 0 to 100. Higher scores indicate fewer symptoms and a better clinical outcome (better quality of life). Change is calculated by subtracting the baseline score from the 12-week score.
Time frame: Baseline and 12-week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.